Pfizer and Allergan have announced that they are abandoning their $160 billion merger. This resulted from a political storm around tax inversions, a technique whereby US companies relocate abroad to avoid the high US corporate tax rates. The Treasury department took action to insert new rules that effectively killed the financial benefits of the deal. …
Tag: Allergan
Middle Market Companies Holding Onto Cash
Instead of investing in growth, companies this year have been holding more than $1.4 trillion in cash – close to a record $1.65 trillion in 2014. Oracle’s $56 billion cash stockpile is 1.5 times its sales and Cisco’s $60 billion in cash is 1.2 times its sales. Eleven companies have cash reserves double their annual …
Pharmaceutical M&A: The Rush to Acquire
Last week alone, there were three major consolidations in the pharmaceutical space: Teva will acquire the generic business of Allergan Hikma pharmaceuticals will acquire Roxane, Boehringer Ingelheim’s generic drug business Mylan will acquire Perrigo These three deals in just a few days reflect the trend of pharmaceutical consolidation as companies seek new products in order to …
Healthcare Services M&A Extraordinarily Strong
Mergers and acquisitions for healthcare services were “extraordinarily strong” in the second quarter of 2014, according to analysis conducted by Scott-Macon. The Affordable Care Act has changed the healthcare industry dramatically, spurring re-alignments across multiple sectors. A wide range of businesses conducted acquisitions in 2Q 2014, including hospitals, private equity, software solution providers and consulting …
Keeping Strategy in Sight When Pursuing Acquisitions
Deferring to advisors during the M&A process can be detrimental to a company, as evidenced by the back and forth over Valeant Pharmaceuticals’ unsolicited $53 billion bid to acquire Allergan, the maker of Botox. The maneuvering over the past several months has become heated and off-track. Or as the Deal Professor column puts it: “Some …
Valeant Seeks More Acquisitions
Valeant Pharmaceuticals International is determined to grow through acquisitions. Already actively pursuing a deal with Allergan, the maker of Botox, Valeant is reportedly seeking another contact lens company. CEO Michael Pearson said the company “will not be content to remain the No. 4 global player in the contact lens industry.” Valeant has a history of …
